Drugs Made In Amer Acqutn (DMAAR) Stock Price, News & Analysis
Company Description
Drugs Made In Amer Acqutn (NASDAQ: DMAAR) is classified in the Blank Checks sector.
DMAAR has declined 18.9% over the past year. Shares last traded at $0.1622.
On a trailing twelve-month basis, Drugs Made In Amer Acqutn reported net income of $5.9M.
This page collects what Stock Titan holds for DMAAR, including price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Drugs Made In Amer Acqutn (DMAAR) stock last traded at $0.1622, down 4.53% from the previous close. Over the past 12 months, the stock has lost 18.9%.
Latest News
SEC Filings
Drugs Made In Amer Acqutn has filed 5 recent SEC filings, including 2 Form 8-K, 2 Form SCHEDULE 13G, 1 Form 10-Q. The most recent filing was submitted on July 20, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all DMAAR SEC filings →
Financial Highlights
operating income reached -$2.8M, and net income was $5.9M. The company generated -$539K in operating cash flow. With a current ratio of 0.03, short-term liquidity bears monitoring.
Upcoming Events
Short Interest History
Short interest in Drugs Made In Amer Acqutn (DMAAR) currently stands at 500 shares, down 57.2% from the previous reporting period. Over the past 12 months, short interest has decreased by 93.0%.
Days to Cover History
Days to cover for Drugs Made In Amer Acqutn (DMAAR) currently stands at 1.0 days. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed. The ratio has shown significant volatility over the period, ranging from 1.0 to 17.9 days.
DMAAR Company Profile & Sector Positioning
Drugs Made In Amer Acqutn (DMAAR) operates in the Blank Checks sector and is listed on the NASDAQ.